Sir Gregory Winter
Sir Gregory Paul Winter FRS is a molecular biologist best known for his work on developing the technologies for making therapeutic monoclonal antibodies.
His inventions have been used in top selling pharmaceutical drugs, especially for treatment of non-infectious diseases, including multiple sclerosis, cancer and rheumatoid arthritis.
His scientific career was based at the MRC Laboratory of Molecular Biology (Cambridge), where he combined his research and administrative duties with the founding of three biotech companies.
Now retired, he continues with his entrepreneurial activities, and is currently a Director of Bicycle Therapeutics plc, a scientific advisor to Ahren Innovation Capital, and a Fellow of Trinity College Cambridge (until recently Master of the College).
He shared the Nobel Prize for Chemistry in 2018.
Kerry Baldwin is the co-founder and Managing Partner of IQ Capital, a UK deep-tech early-stage Venture Capital firm investing from their 5th Fund.
IQ Capital invests in IP rich deep tech with exits to Oracle, Apple, Google, Facebook and several IPOs. Kerry has over 24 years early-stage VC deep tech investment experience.
She is a specialist in Regtech, Suptech, Cybersecurity, Big data investments and guides the wider portfolio through GTM strategies and commercialisation.
Kerry was the 2021/22 Chair of the British Private Equity and Venture Capital Association and is an Honorary Fellow in Entrepreneurship at Cambridge University (Judge Business School).
She is known for her mentoring and promotion of Diversity and inclusion within VC and her PE/VC investment committee and decision-making research. She mentors under-represented founders and first time VC funds and regularly advises Government on Venture Capital and Entrepreneurship.
Formerly leading our Seed Funds team, and now working with the Senior Leadership Team on future projects and planning, Anne has previously overseen strong growth in our investment activities.
Recent highlights include the purchase of Cambridge CMOS Sensors by ams, and the sale of Quethera to Astellas Pharma. Anne has also served on many boards including those of Cambridge CMOS Sensors, Aqdot, Cambridge Touch Technologies, Psyomics, MorphoenIX and Quethera.
She was a founding member of Praxis Auril, which supports Knowledge Exchange Commercialisation in the UK.
Anne’s early career includes experience in technology transfer at Imperial College Innovations Limited, in pharmaceutical development at Evans Medical, and in pharmaceutical product training at Information Transfer.
Anne holds a BSc in Medical Microbiology and a PhD in Immunology.
Anne joined the technology transfer team at the University of Cambridge in 2001, and has been involved with Cambridge Enterprise since its foundation in 2006, including as Interim Director just prior to this. She joined the Seed Funds team in 2008 and was appointed Head of Seed Funds in 2011.